Navigation Links
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Date:5/23/2013

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM).  Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland.  The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions.

"We are deeply honored to receive this recognition from the Tech Council of Maryland," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda.  "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others."

In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Vanda recently announced positive results in the SET and RESET Phase III efficacy studies for Non-24.  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently no treatment for Non-24 has been approved by the U.S. Food and Drug Administration (FDA).  Vanda is targeting a New Drug Application submission with the FDA for tasimelteon in mid-2013.

About The Tech Council of Maryland  
The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland.  TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.  For more information, visit www.techcouncilmd.com.  

About Vanda Pharmaceuticals Inc.  
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Jim Kelly 
Senior Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
2. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
4. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2019)... ... December 07, 2019 , ... The 12-Step ... weekly ongoing face-to-face mutual support groups in 32 countries. At meetings members share ... members also provide several daily phone and internet meetings. This expands the means ...
(Date:12/6/2019)... ... December 06, 2019 , ... Nobilis ... psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration ... the Company to initiate its Phase 2b trial for the treatment of patients ...
(Date:12/6/2019)... Fla. (PRWEB) , ... December 06, 2019 , ... ... preferred distribution agreement with Forbidden Fruit Garden Supply LLC (a division of Horticultural ... its discerning clientele of professional growers. , FFGS is a team of ...
Breaking Medicine Technology:
(Date:12/9/2019)... ... December 09, 2019 , ... WEDI , the nation’s leading nonprofit ... exchange and a trusted advisor to the U.S. Department of Health and Human Services ... Directors, election of Officers* as well as the re-election of ten previous board members ...
(Date:12/9/2019)... ... December 09, 2019 , ... Cocoa Beach is preparing to host its 10th ... most-dazzling Santa-themed gatherings. , What began as a simple family beach day a decade ... tradition. Now, ten years in, there’s no better place for Santa to loosen up ...
(Date:12/8/2019)... ... December 08, 2019 , ... Intelligent.com, a trusted ... 52 Best Homeland Security Degree Programs for 2020. The comprehensive research guide is ... Each program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... frequently, six students in Salt Lake Community College’s (SLCC) Emergency Medical ... Rodgers and Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support ...
(Date:12/6/2019)... ... December 06, 2019 , ... Brain Sentinel, ... Baltimore, Maryland at the AES Annual Meeting. The symposium, “Fundamentals of Quantitative Surface ... methods of quantitative sEMG analysis during ictal events;, 2. Review specific sEMG patterns ...
Breaking Medicine News(10 mins):